Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

Open access
Sadot, Eran, Doussot, Alexandre, O’Reilly, Eileen M., Lowery, Maeve A., Goodman, Karyn A., Do, Richard Kinh Gian, Tang, Laura H., Gönen, Mithat, D’Angelica, Michael I., DeMatteo, Ronald P., Kingham, T. Peter, Jarnagin, William R., Allen, Peter J.·2015·Annals of Surgical Oncology

Abstract

BackgroundReports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FOLFIRINOX.MethodsThe institutional cancer database was queried for patients treated with induction FOLFIRINOX therapy between 2010 and 2013. Patients were included in the study if they were treated at the authors’ institution for stage 3 PDAC (locally unresectable) that had been adjudicated at a weekly multidisciplinary tumor board.ResultsThe study identified 101 patients. The median age was 64 years (range 37–81 years), and the median follow-up period was 12 months (range 3–37 months). The patients received a median of six cycles (range 1–20 cycles) of induction FOLFIRINOX. No grade 4 or 5 toxicity was recorded. At the initial restaging (median of 3 months after diagnosis), 23 patients (23 %) had developed distant metastases, 15 patients (15 %) had undergone resection, and 63 patients (63 %) had proceeded to chemoradiation. In the group of 63 patients who had proceeded to chemoradiation (median of 9 months after diagnosis), an additional 16 patients (16 %) had undergone resection, and 5 patients (5 %) had developed metastases. A partial radiographic response was observed in 29 % of all the patients, which was associated with ability to perform resection (p = 0.004). The median overall survival time was 11 months for the group that progressed with FOLFIRINOX and 26 months for the group that did not progress.ConclusionNearly one third of the patients who had been initially identified as having stage 3 pancreatic carcinoma and had been treated with FOLFIRINOX responded radiographically and underwent tumor resection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1245/s10434-015-4647-4

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 161

Metadata

Authors
Sadot, E., Doussot, A., O’Reilly, E. M., Lowery, M. A., Goodman, K. A., Do, R. K. G., Tang, L. H., Gönen, M., D’Angelica, M. I., DeMatteo, R. P., Kingham, T. P., Jarnagin, W. R., & Allen, P. J.
Venue
Annals of Surgical Oncology
Published
2015-06-12
Volume
22
Issue
11
Pages
3512-3521
ISSN
  • 1068-9265 (ISSN-L)
  • 1534-4681
OpenAlex
W1955000909
Cited by
161
References
2
FWCI
7.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. https://app.cochat.ai/papers/10.1245/s10434-015-4647-4
The paper
Sadot, E., Doussot, A., O’Reilly, E. M., Lowery, M. A., Goodman, K. A., Do, R. K. G., Tang, L. H., Gönen, M., D’Angelica, M. I., DeMatteo, R. P., Kingham, T. P., Jarnagin, W. R., & Allen, P. J. (2015). FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-015-4647-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.